[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579577":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":45,"responsibleParty":60,"collaborators":40,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":40,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":40,"enrollmentInfo":73,"targetDuration":40,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":47,"whyStopped":40,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Kantonsspital Aarau","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Pancrelipase","EXPERIMENTAL","two capsules each containing 15000 USP units of lipase",[13],"Drug: Zenpep",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","two capsules each containing placebo",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Zenpep","two capsules (each containing 15000 USP units of lipase) together with nutritional supplements",[9],[9],{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"two capsules (containing placebo) together with nutritional supplements",[15],[31],"lactose monohydrate",[33],{"name":34,"affiliation":5,"role":35},"Philipp Schuetz, Prof. MD","PRINCIPAL_INVESTIGATOR",[37,42],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},"CONTACT","+41 62 838 68 80",null,"philipp.schuetz@ksa.ch",{"name":43,"role":38,"phone":40,"phoneExt":40,"email":44},"Carla Wunderle","carla.wunderle@ksa.ch",[46],{"facility":5,"status":47,"city":48,"state":40,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"RECRUITING","Aarau","5001","Switzerland","CH",{"type":53,"coordinates":54},"Point",[55,56],8.04422,47.39254,{"lat":56,"lon":55},[59],{"name":34,"role":38,"phone":39,"phoneExt":40,"email":41},{"type":61,"investigatorFullName":62,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":40,"oldOrganization":40},"SPONSOR_INVESTIGATOR","Philipp Schuetz","Prof. MD","100579577","pancrelipase-with-nutritional-supplement-in-patients-at-risk-of-malnutrition-effort-enzo-100579577",false,"NCT06826105","Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO)","Effect of Low Dose Pancrelipase With an Oral Nutritional Supplement to Improve Nutrient Bioavailability in Patients at Increased Risk of Malnutrition","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Male or female 70 years of age or older\n* Hospitalized at site\n* Nutrition Risk Screening 2002 (NRS-2002) ≥ 3\n* eGFR ≥ 30 mL\u002Fmin\u002F1.73 m2 (EPI-CKD) based on medical history (no older than 6 months)\n* Ability to eat orally\n\nExclusion Criteria:\n\n* Patients with acute cardiovascular event ≤ 2 days\n* Patients with terminal conditions\n* Patients diagnosed with pancreatic exocrine insufficiency (EPI) treated with pancreatic enzyme replacement therapy (PERT)\n* Patients having a planned transplant or new-onset dialysis in the next 6 months.\n* Patients having a colectomy, resection of the small intestine or cholecystectomy\n* Known hypersensitivity to any of the substances or excipients of the ONS or the medicinal product","ALL","70 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"NA","This study investigates if pancreatic enzymes in combination with oral nutritional supplement can improve nutrient bioavailability in older people with malnutrition or at risk of malnutrition.",[81],"Malnutrition",[9,83],"Oral nutritional supplements","2025-09-24",{"date":86,"type":87},"2025-09-30","ACTUAL",{"date":89,"type":87},"2025-09-22",{"date":91,"type":75},"2026-01",{"name":62,"class":6},1]